SEC Form 4 · accession 0000899243-18-019501
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pablo J Cagnoni
Director
Period of report
Jul 3, 2018
Accepted (ET)
Jul 5, 2018 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jul 3, 2018 | M | 5,816 | $5.59 | A | 5,816 | D | |
| Common Shares | Jul 3, 2018 | S | 5,816 | $62.00 | D | 0 | D | |
| Common Shares | Jul 5, 2018 | M | 1,684 | $5.59 | A | 1,684 | D | |
| Common Shares | Jul 5, 2018 | S | 1,684 | $62.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $5.59 | Jul 3, 2018 | M | 5,816 | A | — | Nov 4, 2025 | Common Shares | 5,816 | 88,017 | D |
| Stock Option (Right to Buy)F2 | $5.59 | Jul 5, 2018 | M | 1,684 | A | — | Nov 4, 2025 | Common Shares | 1,684 | 86,333 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.